A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China : A multicenter, cross-sectional study
© 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society..
BACKGROUND: Studies on various thrombopoietic agents for cancer treatment-induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens.
METHODS: In this retrospective, cross-sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL-11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO-RA). The outcomes, compliance, and safety of different treatments were analyzed.
RESULTS: Among the 1437 analyzable cases, most patients were treated with either rhTPO alone (49.3%) or rhIL-11 alone (27.0%). The most common combination regimen used was rhTPO and rhIL-11 (10.9%). Platelet transfusions were received by 117 cases (8.1%). In multivariate analysis, rhTPO was associated with a significantly lower proportion of platelet recovery, platelet transfusion, and hospitalization due to chemotherapy-induced thrombocytopenia (CIT) than rhIL-11 alone. No significant difference was observed in the time taken to achieve a platelet count of >100 × 109/L and chemotherapy dose reduction due to CIT among the different thrombopoietic agents. The outcomes of thrombocytopenia in 170 patients who received targeted therapy and/or immunotherapy are also summarized. The results show that the proportion of platelet recovery was similar among the different thrombopoietic agents. No new safety signals related to thrombopoietic agents were observed in this study. A higher proportion of physicians preferred to continue treatment with TPO-RA alone than with rhTPO and rhIL-11.
CONCLUSIONS: This survey provides an overview of CTIT and the application of various thrombopoietic agents throughout China. Comparison of monotherapy with rhIL-11, rhTPO, and TPO-RA requires further randomized clinical trials. The appropriate application for thrombopoietic agents should depend on the pretreatment of platelets, treatment variables, and risk of bleeding.
PLAIN LANGUAGE SUMMARY: To provide an overview of the outcome of cancer treatment-induced thrombocytopenia in China, our cross-sectional study analyzed 1437 cases treated with different thrombopoietic agents. Most of the patients were treated with recombinant interleukin 11 (rhIL-11) and recombinant thrombopoietin (rhTPO). rhTPO was associated with a significantly lower proportion of platelet recovery and platelet transfusion compared with rhIL-11.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:130 |
|---|---|
| Enthalten in: |
Cancer - 130(2024), S8 vom: 15. Apr., Seite 1524-1538 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Meiting [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.04.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cncr.35292 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370049616 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370049616 | ||
| 003 | DE-627 | ||
| 005 | 20240410232743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cncr.35292 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM370049616 | ||
| 035 | |a (NLM)38515388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Meiting |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China |b A multicenter, cross-sectional study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.04.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. | ||
| 520 | |a BACKGROUND: Studies on various thrombopoietic agents for cancer treatment-induced thrombocytopenia (CTIT) in China are lacking. This study aimed to provide detailed clinical profiles to understand the outcomes and safety of different CTIT treatment regimens | ||
| 520 | |a METHODS: In this retrospective, cross-sectional study, 1664 questionnaires were collected from 33 hospitals between March 1 and July 1, 2021. Patients aged >18 years were enrolled who were diagnosed with CTIT and treated with recombinant interleukin 11 (rhIL-11), recombinant thrombopoietin (rhTPO), or a thrombopoietin receptor agonist (TPO-RA). The outcomes, compliance, and safety of different treatments were analyzed | ||
| 520 | |a RESULTS: Among the 1437 analyzable cases, most patients were treated with either rhTPO alone (49.3%) or rhIL-11 alone (27.0%). The most common combination regimen used was rhTPO and rhIL-11 (10.9%). Platelet transfusions were received by 117 cases (8.1%). In multivariate analysis, rhTPO was associated with a significantly lower proportion of platelet recovery, platelet transfusion, and hospitalization due to chemotherapy-induced thrombocytopenia (CIT) than rhIL-11 alone. No significant difference was observed in the time taken to achieve a platelet count of >100 × 109/L and chemotherapy dose reduction due to CIT among the different thrombopoietic agents. The outcomes of thrombocytopenia in 170 patients who received targeted therapy and/or immunotherapy are also summarized. The results show that the proportion of platelet recovery was similar among the different thrombopoietic agents. No new safety signals related to thrombopoietic agents were observed in this study. A higher proportion of physicians preferred to continue treatment with TPO-RA alone than with rhTPO and rhIL-11 | ||
| 520 | |a CONCLUSIONS: This survey provides an overview of CTIT and the application of various thrombopoietic agents throughout China. Comparison of monotherapy with rhIL-11, rhTPO, and TPO-RA requires further randomized clinical trials. The appropriate application for thrombopoietic agents should depend on the pretreatment of platelets, treatment variables, and risk of bleeding | ||
| 520 | |a PLAIN LANGUAGE SUMMARY: To provide an overview of the outcome of cancer treatment-induced thrombocytopenia in China, our cross-sectional study analyzed 1437 cases treated with different thrombopoietic agents. Most of the patients were treated with recombinant interleukin 11 (rhIL-11) and recombinant thrombopoietin (rhTPO). rhTPO was associated with a significantly lower proportion of platelet recovery and platelet transfusion compared with rhIL-11 | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer treatment–induced thrombocytopenia | |
| 650 | 4 | |a chemotherapy‐induced thrombocytopenia | |
| 650 | 4 | |a cross‐sectional study | |
| 650 | 4 | |a recombinant interleukin 11 | |
| 650 | 4 | |a recombinant thrombopoietin | |
| 650 | 4 | |a thrombopoietic agents | |
| 650 | 4 | |a thrombopoietin receptor agonist | |
| 650 | 7 | |a Interleukin-11 |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Thrombopoietin |2 NLM | |
| 650 | 7 | |a 9014-42-0 |2 NLM | |
| 700 | 1 | |a Li, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaobing |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Zijun |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Qingyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yanqiao |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Liting |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Xianglin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhehai |e verfasserin |4 aut | |
| 700 | 1 | |a Xue, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a An, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Kangsheng |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Mei |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiaojia |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Enxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Jincai |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Yongqian |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Nong |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Huaqing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Runxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tianshu |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Ting |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Liao, Wangjun |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Wensheng |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Mingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ruilian |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xiaoling |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Jifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Ba, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yanxia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer |d 1948 |g 130(2024), S8 vom: 15. Apr., Seite 1524-1538 |w (DE-627)NLM000028649 |x 1097-0142 |7 nnns |
| 773 | 1 | 8 | |g volume:130 |g year:2024 |g number:S8 |g day:15 |g month:04 |g pages:1524-1538 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cncr.35292 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 130 |j 2024 |e S8 |b 15 |c 04 |h 1524-1538 | ||